RESERPINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H40N2O9
Molecular Weight	608.68
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COc1ccc2c3CCN4C[C@@]5([H])C[C@]([H])([C@@]([H])([C@]([H])([C@@]5([H])C[C@]4([H])c3[nH]c2c1)C(=O)OC)OC)OC(=O)c6cc(c(c(c6)OC)OC)OC

InChI

InChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N

InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C33H40N2O9
Molecular Weight	608.68
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462 | https://www.ncbi.nlm.nih.gov/pubmed/15529229 | https://www.ncbi.nlm.nih.gov/pubmed/23831411

Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vesicular amine transporter 1 6 Target ID: CHEMBL1838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 511		160.0 nM [IC50]
Synaptic vesicular amine transporter 48 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23831411	Blocker 511		350.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 515 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Primary		Approved 8043	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11
Agitated psychotic states 6 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a4d74d7-2e63-4789-b50e-af17ced92462	Palliative		Approved 8043	RESERPINE Approved Use Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication. Launch Date -4.66300797E11

C_max

Value	Dose	Co-administered	Analyte	Population
0.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
23.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/30465727	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:		RESERPINE plasma	Equus caballus population: HEALTHY age: ADULT sex: MALE food status: FED

Doses

Dose	Population	Adverse events
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Drowsiness, Light headedness... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Light headedness (light, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	Disc. AE: Upper abdominal pain, Postural hypotension... AEs leading to discontinuation/dose reduction: Upper abdominal pain (1 patient) Postural hypotension (1 patient) Electrocardiogram abnormal (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Light headedness	light, 1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Electrocardiogram abnormal	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Postural hypotension	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352
Upper abdominal pain	1 patient Disc. AE	0.25 mg 2 times / day multiple, oral Dose: 0.25 mg, 2 times / day Route: oral Route: multiple Dose: 0.25 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17628352	unhealthy, 41.2 years n = 60 Health Status: unhealthy Condition: cocaine dependence Age Group: 41.2 years Sex: M+F Population Size: 60 Sources: https://pubmed.ncbi.nlm.nih.gov/17628352

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467 activator 74	inhibitor 1604	inhibitor 1702	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1330 BSEP 376 BCRP 643 MRP2 346 OATP1B1 733 OATP1B3 657 OATP2B1 109 CYP1A2 1383 CYP2C19 1325 CYP2A6 627 CYP2E1 790 Kv1.3 16 MRP3 150 MRP4 194	P-gp 1400	P-gp 248 CYP3A4/5 108

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1772	activator 202 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	no [Activation >3.9811 uM]
CYP2A6 659	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 871	inhibitor 3045 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP1A2 1532	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
CYP2C9 1648	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	no
OATP1B3 666	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	unlikely [Inhibition 20 uM]
MRP3 200	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
MRP4 226	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	weak [IC50 133 uM]
Kv1.3 31	inhibitor 3045 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706	weak [IC50 58 uM]
BSEP 377	inhibitor 3045 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/19520776/	yes [IC50 2.8 uM]
CYP3A4 1772	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/11743742/, https://pubmed.ncbi.nlm.nih.gov/24396142/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzcyIn19	yes [IC50 20.4 uM]
BCRP 713	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/, https://pubmed.ncbi.nlm.nih.gov/17430633/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50017712, https://pubmed.ncbi.nlm.nih.gov/23956101/	yes [IC50 26.3 uM]
CYP2C19 1392	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.03 uM]
CYP2D6 1738	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/24396142/	yes [IC50 <0.2 uM]
OATP1B1 748	inhibitor 3045 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
OATP2B1 112	inhibitor 3045 Sources: https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/22541068/	yes [Inhibition 20 uM]
P-gp 1514	inhibitor 3045 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/10080959/, http://transportal.compbio.ucsf.edu/compounds/reserpine/, https://pubmed.ncbi.nlm.nih.gov/12134945/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc3MiJ9fQ%3D%3D	yes [Ki 1.38 uM]
MRP2 434	inhibitor 3045 Sources: http://transportal.compbio.ucsf.edu/compounds/reserpine/,https://go.drugbank.com/drugs/DB00206, https://pubmed.ncbi.nlm.nih.gov/12134946/, https://pubmed.ncbi.nlm.nih.gov/23956101/, https://www.genome.jp/kegg/drug/br08309.html, https://pubmed.ncbi.nlm.nih.gov/18457386/	yes [Ki 295 uM]
CYP3A4/5 293	inducer 1440 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes
P-gp 1514	inducer 1440 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000050555, https://pubmed.ncbi.nlm.nih.gov/8632764/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/31571164/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X11000706

PubMed

Title	Date	PubMed
Effects of aminergic drugs and glutamic acid on audiogenic seizures induced by early exposure to ethanol.	1975 Mar	123503
[Behavior pharmacology of maprotiline, a new antidepressant].	1975 Nov	1240830
[Characterization and recognition key components in Astragalus membranaceus].	2001 Jul	12585085
[Determination of intestinal trefoil factor in burned rats by reversed-phase high performance liquid chromatography].	2001 Jul	12545493
[Recognition and quantitative contrast characteristic components for root of Chinese angelica].	2001 Mar	12541663
[Determination of bifonazole in cream by high performance liquid chromatography].	2001 May	12541819
[Study of diphacinone in biological samples by high performance liquid chromatography/diode array detector].	2001 May	12541808
[Determination of acyclovir in mouse plasma and tissues by reversed-phase high performance liquid chromatography].	2001 Nov	12545469
Studies on the cardiotoxicity of noradrenaline in isolated rabbit hearts.	2002	12189778
Identification of mammary carcinogens in rodent bioassays.	2002	11921183
Behavioral effects of MK-801 on reserpine-treated mice.	2002 Apr	11999899
Heterologous expression of a Rauvolfia cDNA encoding strictosidine glucosidase, a biosynthetic key to over 2000 monoterpenoid indole alkaloids.	2002 Apr	11985599
Augmentation of immune cell activity against tumor cells by Rauwolfia radix.	2002 Aug	12127238
High-performance liquid chromatographic, capillary electrophoretic and capillary electrophoretic-electrospray ionisation mass spectrometric analysis of selected alkaloid groups.	2002 Aug 16	12219932
[Determination of ofloxacin in human fallopian tube, uterus and serum by high performance liquid chromatography].	2002 Feb	12579960
Temperature effect on peak width and column efficiency in subcritical water chromatography.	2002 Feb	11881703
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.	2002 Jan-Feb	11980384
[Application of fingerprint chromatogram in quality control of Shen-Mai injection].	2002 Jul	12541909
Determination of L-sesamin and L-asarinin in Zanthoxylum(Roxb.) DC. by high performance liquid chromatography.	2002 Jul	12376305
Increase of free cysteine and citric acid in plant cells exposed to cobalt ions.	2002 Jul	12052512
Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.	2002 Jul 31	12093527
Validated HPLC method for determination of sennosides A and B in senna tablets.	2002 Jul 31	12093522
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.	2002 Jul 31	12093510
Rapid high-performance liquid chromatographic assay of dorzolamide in rabbit aqueous humor.	2002 Jun	11933028
Determination of ethylenediamine tetraacetic acid in injection forms by ion-pair chromatography.	2002 Jun 15	12049972
Simultaneous determination of N-oxides and free bases of pyrrolizidine alkaloids by cation-exchange solid-phase extraction and ion-pair high-performance liquid chromatography.	2002 Mar 8	11999741
Validation of a simple liquid chromatographic method for determination and quantitation of residual ivermectin and doramectin in pig liver.	2002 Mar-Apr	11990020
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].	2002 May	12774329
[Determination of aspirin and free salicylic acid in lysinipirine injection by high performance liquid chromatography].	2002 May	12541957
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.	2002 Nov 7	12408906
Determination of undecylenic and sorbic acids in cosmetic preparations by high performance liquid chromatography with electrochemical detection.	2002 Nov 7	12408884
A modified HPLC method for the determination of ochratoxin A by fluorescence detection.	2002 Oct	12378560
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.	2002 Oct	12235267
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.	2002 Oct 4	12416886
The physiology of overwintering in a turtle that occupies multiple habitats, the common snapping turtle (Chelydra serpentina).	2002 Sep-Oct	12529844
Osteology and skeletal development of Apalone spinifera (Reptilia: Testudines: Trionychidae).	2003 Apr	12616574
Expression of heart K+ channels in adrenalectomized and catecholamine-depleted reserpine-treated rats.	2003 Feb	12606256
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.	2003 Feb	12539206
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.	2003 Feb 1	12576053
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.	2003 Feb 10	12569393
DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.	2003 Feb 24	12592376
Optimization and validation of conventional and micellar LC methods for the analysis of methyltestosterone in sugar-coated pills.	2003 Feb 5	12560066
Analysis of selected withanolides in plant extract by capillary electrochromatography and microemulsion electrokinetic chromatography.	2003 Jan	12569525
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.	2003 Jan 14	12525265
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.	2003 Jan-Feb	12587684
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.	2003 Jun	12711835
Rat stomach ECL cells: mode of activation of histidine decarboxylase.	2003 Jun 15	12763636
Studies on the long-term thermal stability of stationary phases in subcritical water chromatography.	2003 Mar 7	12641282
Assessment of a controlled release hydrophilic matrix formulation for metoclopramide HCl.	2003 May	12754009
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.	2003 May 21	12748199

Patents

Sample Use Guides

In Vivo Use Guide

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Jun 25 20:57:12 UTC 2021` Edited by `admin` on `Fri Jun 25 20:57:12 UTC 2021`
Record UNII	8B1QWR724A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RESERPINE

Official Name

English

RESERPINE COMPONENT OF CAM-AP-ES

Common Name

English

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT RESERPINE

Common Name

English

YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-

Common Name

English

SERPASIL

Brand Name

English

HYDRAP-ES COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SER-A-GEN

Common Name

English

RESERPINE [WHO-IP]

Common Name

English

METATENSIN COMPONENT RESERPINE

Common Name

English

RESERPINE [JAN]

Common Name

English

ENT-50146

Code

English

RESERPINE COMPONENT OF HYDROMOX R

Common Name

English

SANDRIL

Brand Name

English

RESERPINE [MI]

Common Name

English

REGROTON COMPONENT RESERPINE

Common Name

English

CAM-AP-ES COMPONENT RESERPINE

Common Name

English

RESERPINE [USP MONOGRAPH]

Common Name

English

DIUTENSEN-R COMPONENT RESERPINE

Common Name

English

RESERPINE [ORANGE BOOK]

Common Name

English

SER-A-GEN COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

Common Name

English

RESERPINE [EP MONOGRAPH]

Common Name

English

RESERPINE COMPONENT OF SALUTENSIN

Common Name

English

RESERPINE [MART.]

Common Name

English

RESERPINE COMPONENT OF DIUTENSEN-R

Common Name

English

HYDROSERPINE PLUS (R-H-H) COMPONENT RESERPINE

Common Name

English

RAU-SED

Brand Name

English

RESERPINE [HSDB]

Common Name

English

NSC-237659

Code

English

RESERPINE COMPONENT OF DRALSERP

Common Name

English

RESERPINE [WHO-DD]

Common Name

English

RESERPINE COMPONENT OF METATENSIN

Common Name

English

RESERPINE COMPONENT OF HYDROPRES

Common Name

English

RESERPINUM [WHO-IP LATIN]

Common Name

English

RENESE-R COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SERPASIL-ESIDRIX

Common Name

English

RESERPINUM

Common Name

English

RESERPINE COMPONENT OF RENESE-R

Common Name

English

H.R.-50 COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF HYDRO-RESERP

Common Name

English

RESERPINE COMPONENT OF REGROTON

Common Name

English

RESERPINE COMPONENT OF HYDRAP-ES

Common Name

English

RESERPINE [VANDF]

Common Name

English

RESERPINE COMPONENT OF DEMI-REGROTON

Common Name

English

RESERPINE COMPONENT OF SERPASIL-APRESOLINE

Common Name

English

HYDROMOX R COMPONENT RESERPINE

Common Name

English

DEMI-REGROTON COMPONENT RESERPINE

Common Name

English

SERPASIL-ESIDRIX COMPONENT RESERPINE

Common Name

English

RESERPINE [IARC]

Common Name

English

RESERPINE COMPONENT OF UNIPRES

Common Name

English

RESERPINE COMPONENT OF NAQUIVAL

Common Name

English

APOPLON

Brand Name

English

RESERPINE [USP-RS]

Common Name

English

RESERPINE COMPONENT OF H.R.-50

Common Name

English

SERPASIL-APRESOLINE COMPONENT RESERPINE

Common Name

English

HYDROPRES COMPONENT RESERPINE

Common Name

English

SERPALAN

Brand Name

English

HYDRO-RESERP COMPONENT RESERPINE

Common Name

English

RESERPINUM [HPUS]

Common Name

English

RESERPINE [INN]

Common Name

English

SALUTENSIN COMPONENT RESERPINE

Common Name

English

RESERPINE COMPONENT OF SER-AP-ES

Common Name

English

RESERPINE COMPONENT OF HYDROSERPINE PLUS (R-H-H)

Common Name

English

NSC-59272

Code

English

DRALSERP COMPONENT RESERPINE

Common Name

English

UNIPRES COMPONENT RESERPINE

Common Name

English

METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER).

Common Name

English

NAQUIVAL COMPONENT RESERPINE

Common Name

English

METHYL (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)YOHIMBAN-16-CARBOXYLATE

Common Name

English

SER-AP-ES COMPONENT RESERPINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

C02LA71